Postadulticide pulmonary hypertension of canine heartworm disease: successful treatment with oxygen and failure of antihistamines.
Postadulticide pulmonary hypertension mechanisms and treatment with antihistamines and supplemental oxygen were studied in eight dogs with heartworm disease. To ensure severe postadulticide thromboembolism, additional heartworms (either 20 or 40 into 4 dogs each) were transplanted into naturally infected dogs before thiacetarsamide treatment. During pentobarbital anesthesia, 2 pulmonary hemodynamic studies were conducted on each dog with a sequence of baseline, hypoxia with FlO2 = 10%, hyperoxia with FlO2 = 100%, a second baseline, treatment with either diphenhydramine (D) or cimetidine (C), and another hypoxia. All dogs were pulmonary hypertensive, with each dog having a mean pulmonary arterial pressure (PPA) greater than 20 mm of Hg. Mean PPA increased from baseline conditions (25.0 +/- 4.5 SD for D and 24.3 +/- 4.4 for C) to hypoxia (28.5 +/- 4.7 for D and 28.4 +/- 3.7 for C), and decreased during hyperoxia (16.9 +/- 3.0 for D and 17.4 +/- 3.0 for C), respectively. Neither antihistamine reduced PPA at normoxia. The degree of pulmonary hypertension when breathing room air increased even more during hypoxia, and this increase was not attenuated by either antihistamine. Histamine did not appear to mediate pulmonary hypertension during postadulticide thromboembolism, nor to modify the hypoxia-mediated pulmonary hypertension at this disease stage. Because baseline PO2 was low (66.6 +/- 11.7 mm of Hg for D and 69.4 +/- 14.2 for C) and because PPA decreased during administration of oxygen, the pulmonary hypertension was mostly hypoxia-induced. In addition to the arterial lesions, much of the pulmonary hypertensive mechanism was an active and reversible vasoconstriction in response to hypoxia caused by the secondary lung disease.(ABSTRACT TRUNCATED AT 250 WORDS)
Rawlings
C A
CA
Department of Small Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602.
Tackett
R L
RL
D000818:Animals; D001148:Arsenamide / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002927:Cimetidine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004155:Diphenhydramine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004184:Dirofilariasis / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000209:etiology* / Q000628:therapy; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000628:therapy / Q000662:veterinary*; D000860:Hypoxia / Q000188:drug therapy / Q000662:veterinary; D010100:Oxygen / Q000627:therapeutic use*
D002927:Cimetidine; D004155:Diphenhydramine; D010100:Oxygen; D001148:Arsenamide